Bio-Techne Announces 2018 Investor Day And Webcast

MINNEAPOLIS, Aug. 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host its 2018 Investor Day on Friday, September 7, 2018, starting at 9:00 a.m. EDT. The meeting will take place at the Lotte New York Palace Hotel, 455 Madison Avenue, New York City.


The Investor Day will feature presentations from members of Bio-Techne's senior leadership team followed by Q&A.

Interested institutional investors and analysts unable to attend are invited to access the live webcast or a replay of the meeting by going to the Investor Relations section of the Bio-Techne website at

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in-situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.  The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 2,000 employees worldwide. For more information on Bio-Techne and its brands, please visit


David Clair, Investor Relations



Cision View original content with multimedia:

SOURCE Bio-Techne Corporation